CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC)

BACKGROUND: Cisplatin (DDP) is the first-line chemotherapeutic drug for non-small cell lung cancer (NSCLC), and long-term DDP stimulation increased resistance of NSCLC cells to this drug by enriching cancer stem cells (CSCs), which contributed to recurrence and worse prognosis of NSCLC, but the mole...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yongsheng, Zheng, Renyan, Chen, Jian, Ning, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339514/
https://www.ncbi.nlm.nih.gov/pubmed/32655321
http://dx.doi.org/10.1186/s12935-020-01390-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339514/
https://www.ncbi.nlm.nih.gov/pubmed/32655321
http://dx.doi.org/10.1186/s12935-020-01390-w

Ejemplares similares